F13B sirna

F13B siRNA (Human)

Cat. Num. AAA8237056

• Gene Names: F13B; FXIIIB
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: F13B; F13B siRNA (Human); Coagulation factor XIII B chain; Fibrin-stabilizing factor B subunit; Protein-glutamine gamma-glutamyltransferase B chain; Transglutaminase B chain; F13B sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: F13B siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 661

• Applicable Applications for F13B sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human F13B gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for F13B sirna

siRNA to inhibit F13B expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 110611237
• NCBI GeneID: 2165
• NCBI Accession #: NP_001985.2
• NCBI GenBank Nucleotide #: NM_001994.2
• UniProt Accession #: P05160; Q5VYL5; A8K3E5
• Molecular Weight: 75,511 Da
• NCBI Official Full Name: coagulation factor XIII B chain
• NCBI Official Synonym Full Names: coagulation factor XIII, B polypeptide
• NCBI Official Symbol: F13B
• NCBI Official Synonym Symbols: FXIIIB
• NCBI Protein Information: coagulation factor XIII B chain
• UniProt Protein Name: Coagulation factor XIII B chain
• Protein Family: Coagulation factor
• UniProt Gene Name: F13B
• UniProt Entry Name: F13B_HUMAN

NCBI Description

This gene encodes coagulation factor XIII B subunit. Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as a plasma carrier molecules. Platelet factor XIII is comprised only of 2 A subunits, which are identical to those of plasma origin. Upon activation by the cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion. [provided by RefSeq, Jul 2008]

Uniprot Description

F13B: The B chain of factor XIII is not catalytically active, but is thought to stabilize the A subunits and regulate the rate of transglutaminase formation by thrombin. Defects in F13B are the cause of factor XIII subunit B deficiency (FA13BD). FA13BD is an autosomal recessive disorder characterized by a life-long bleeding tendency, impaired wound healing and spontaneous abortion in affected women.

Protein type: Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 1q31-q32.1

Cellular Component: extracellular region

Biological Process: blood coagulation

Disease: Factor Xiii, B Subunit, Deficiency Of